Biotech Stock Report: Reviewing InterMune, Advaxis, Inc & Amgen, Inc

biotech_industry_08-512x384

Here in this article, we take a good look at three upcoming Biotech Stocks, namely, InterMune, Advaxis, Inc & Amgen, Inc.

InterMune Inc (NASDAQ ITMN) listed its shares as a big mover previous session, as its shares jumped over 35% after Roche AG’s declaration it would buy the respiratory-drug maker for $8.3B, in spite of InterMune’s relatively small array of drugs in its pipeline. According to Analysts, the deal makes for a good fit as InterMune area of expertise in pulmonary drugs makes it a good fit for Roche (RHHBY), the Swiss pharmaceutical giant.

After opening of market, InterMune Inc (NASDAQ ITMN) shares hit its intraday high price of $73.18 moreover then finished at $72.85 by shares raised 35.41% in last trading session. The Wall Street consensus average estimates for latest quarter revenue are $37.65M at the same time as 13 experts forecast $43.07M revenues for the next three months of 2014.

Biotech Stock News

Advaxis, Inc (NASDAQ ADXS) reported on Monday that it will test an experimental immuno-oncology drug in combination with a high-profile immunotherapy from Merck & Co Inc (MRK) as a treatment for patients with advanced prostate cancer. Chief executive officer of Advaxis, Daniel O’Connor, stated that if the combination of drugs shows an added effect, the firms would likely continue their collaboration, perhaps under a licensing deal. The trading performance in last session was noticeable, Advaxis, Inc. (NASDAQ ADXS), stocks surged 23.08% with market capitalization of $62.64M on outstanding shares of $19.27M.

On the other hand, Amgen, Inc (NASDAQ AMGN) persists to progress with its pipeline. Earlier in Aug, the firm reported optimistic encouraging data from the phase III ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone as compare to Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) study on multiple myeloma treatment, Kyprolis. Amgen, Inc (NASDAQ AMGN) has gain at 1.48% with closing price of $134.79 shares. Its market capitalization was recorded $100.89B. In last 30 days, shares have increase 9.73% and 17.9% in previous three months.

Biotech News Video

Watch this video for more “Biotech” news.

[grabpress_video guid=62c4a5774f3266964d11a28ba963bd81ebc72453 embed_id=2151917]

Biotech Financial News

All the three stocks look promising for a biotech investor. Stay tuned to technews to find how these stocks fare out in the coming months. Stay updated with major biotech news.

Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone